Bafna Pharmaceuticals Limited (BOM:532989)
India · Delayed Price · Currency is INR 247.00
+4.80 (1.98%)
At close: Aug 21, 2026
Bafna Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 5,735 | 2,587 | 1,769 | 1,853 | 1,940 | 2,996 | |
Market Cap Growth | 133.84% | 46.18% | -4.53% | -4.45% | -35.25% | -7.86% |
Enterprise Value | 6,090 | 2,908 | 1,945 | 1,941 | 2,104 | 3,042 |
Last Close Price | 247.00 | 113.00 | 75.00 | 76.66 | 82.65 | 127.00 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 73.66 | 23.30 | 42.61 | 25.23 | 17.11 | 57.44 |
PS Ratio | 4.02 | 1.72 | 1.21 | 1.22 | 1.68 | 3.52 |
PB Ratio | 5.97 | 2.69 | 2.09 | 2.29 | 2.64 | 4.84 |
P/TBV Ratio | 5.97 | 2.69 | 2.09 | 2.34 | 2.70 | 4.84 |
P/FCF Ratio | - | - | 640.66 | - | - | 136.99 |
P/OCF Ratio | 37.31 | 16.83 | 7.99 | 19.54 | 39.17 | 30.80 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.27 | 1.93 | 1.33 | 1.27 | 1.82 | 3.57 |
EV/EBITDA Ratio | 52.29 | 18.24 | 16.43 | 15.74 | 12.30 | 25.07 |
EV/EBIT Ratio | 115.39 | 29.45 | 27.98 | 26.45 | 17.88 | 45.81 |
EV/FCF Ratio | - | - | 704.05 | - | - | 139.09 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.39 | 0.39 | 0.33 | 0.30 | 0.31 | 0.18 |
Debt / EBITDA Ratio | 3.21 | 2.35 | 2.38 | 1.98 | 1.34 | 0.91 |
Debt / FCF Ratio | - | - | 102.10 | - | - | 5.06 |
Net Debt / Equity Ratio | 0.37 | 0.37 | 0.29 | 0.28 | 0.21 | 0.18 |
Net Debt / EBITDA Ratio | 3.04 | 2.22 | 2.09 | 1.87 | 0.88 | 0.90 |
Net Debt / FCF Ratio | - | -3.71 | 89.67 | -3.77 | -8.56 | 4.98 |
Asset Turnover | - | 0.92 | 0.97 | 1.10 | 1.05 | 0.96 |
Inventory Turnover | - | 3.60 | 3.58 | 4.14 | 3.62 | 2.89 |
Quick Ratio | - | 0.80 | 0.84 | 0.87 | 1.05 | 0.68 |
Current Ratio | - | 1.57 | 1.66 | 1.73 | 1.88 | 2.31 |
Return on Equity (ROE) | - | 12.27% | 5.01% | 9.53% | 16.74% | 8.79% |
Return on Assets (ROA) | - | 3.76% | 2.89% | 3.31% | 6.70% | 4.70% |
Return on Invested Capital (ROIC) | 4.01% | 8.19% | 6.51% | 7.63% | 14.24% | 9.25% |
Return on Capital Employed (ROCE) | - | 8.30% | 6.90% | 7.80% | 14.20% | 9.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.36% | 4.29% | 2.35% | 3.96% | 5.85% | 1.74% |
FCF Yield | -1.66% | -3.69% | 0.16% | -3.29% | -0.91% | 0.73% |
Buyback Yield / Dilution | -1.32% | -0.05% | - | - | - | 0.13% |